PMID- 29935903
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20221207
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 44
IP  - 6
DP  - 2017 Dec
TI  - Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel 
      for treatment of metastatic pancreatic cancer "in a Korean" population: A 
      single-center cohort study.
PG  - 420-427
LID - S0093-7754(17)30139-2 [pii]
LID - 10.1053/j.seminoncol.2018.01.001 [doi]
AB  - Pancreatic cancer has poor prognosis because of its rapid progression and 
      treatment resistance. Based on the results of the Metastatic Pancreatic 
      Adenocarcinoma Clinical Trial (MPACT), a combination regimen of gemcitabine with 
      nab-paclitaxel is currently used as standard therapy for the treatment of 
      metastatic pancreatic cancer. However, because studies in Asian populations are 
      lacking, we investigated the treatment efficacy and safety of this combination 
      therapy in Korean population. Patients with metastatic pancreatic cancer (n=81) 
      treated with gemcitabine and nab-paclitaxel (1,000 and 125 mg/m(2), respectively) 
      as the first-line chemotherapy from January 2016 were identified using the 
      Severance Hospital Pancreatic Cancer Cohort Registry. Treatment efficacy and 
      treatment-related adverse events (AEs) were analyzed. The median follow-up period 
      was 10.7 months (range, 1.5-23.3 months). Median overall survival, 
      progression-free survival, and objective response rates were 12.1 months (95% 
      confidence interval [CI], 10.7-not estimable), 8.4 months (95% CI, 5.0-11.8), and 
      46.9%, respectively. The incidence of grade >/=3 neurotoxicity and neutropenia were 
      18.5% and 46.9%, respectively. Febrile neutropenia and grade >/=3 gastrointestinal 
      AEs occurred in 13 (16.0%) and 16 (19.8%) patients, respectively. Dose reductions 
      because of AEs were required in 60.5% of patients. The combination of gemcitabine 
      with nab-paclitaxel is an effective anti-cancer regimen in Korean population of 
      patients with metastatic pancreatic adenocarcinoma. However, careful monitoring 
      and management are required because of occurrence of treatment-related AEs.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Cho, In Rae
AU  - Cho IR
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Kang, Huapyong
AU  - Kang H
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Jo, Jung Hyun
AU  - Jo JH
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Lee, Hee Seung
AU  - Lee HS
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Chung, Moon Jae
AU  - Chung MJ
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Park, Jeong Youp
AU  - Park JY
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Park, Seung Woo
AU  - Park SW
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Song, Si Young
AU  - Song SY
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Chung, Jae Bock
AU  - Chung JB
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - An, Chansik
AU  - An C
AD  - Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Park, Mi-Suk
AU  - Park MS
AD  - Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Jung, So Young
AU  - Jung SY
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Bang, Seungmin
AU  - Bang S
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea. Electronic address: bang7028@yuhs.ac.
LA  - eng
PT  - Journal Article
DEP - 20180112
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - 0W860991D6 (Deoxycytidine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/secondary
MH  - Adult
MH  - Aged
MH  - Albumins/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Asian People
MH  - Cohort Studies
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/secondary
MH  - Lung Neoplasms/*drug therapy/secondary
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Nervous System Diseases/chemically induced
MH  - Neurotoxicity Syndromes/etiology
MH  - Neutropenia/chemically induced
MH  - Paclitaxel/administration & dosage
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Peritoneal Neoplasms/*drug therapy/secondary
MH  - Progression-Free Survival
MH  - Republic of Korea
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Gemcitabine
OTO - NOTNLM
OT  - chemotherapy
OT  - gemcitabine
OT  - nab-paclitaxel
OT  - pancreatic cancer
OT  - prognosis
EDAT- 2018/06/25 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/06/25 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2017/12/27 00:00 [revised]
PHST- 2018/01/01 00:00 [accepted]
PHST- 2018/06/25 06:00 [entrez]
PHST- 2018/06/25 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
AID - S0093-7754(17)30139-2 [pii]
AID - 10.1053/j.seminoncol.2018.01.001 [doi]
PST - ppublish
SO  - Semin Oncol. 2017 Dec;44(6):420-427. doi: 10.1053/j.seminoncol.2018.01.001. Epub 
      2018 Jan 12.